Genekam filed EU antitrust complaint against Twitter
Genekam has developed
ultrasensitive Magnetic beads ELISA for SARS CoV-2
Our technology and applications:
1. In vitro primary immunisation of human B-lymphocytes with different antigens e.g. viral, parasite bacterial antigens (primary immunisation): This technology offers a biggest advantage that one can immunise the lymphocytes with those antigens, which are toxic to human beings e.g. snake venom. This makes also possible to get the immunised lymphocytes against the diseases, which has been eradicated e.g. small pox or not present in one part of the world. One can do this method to get the immunised cells against the highly infectious agents, which are difficult to culture or there is a need to have high security laboratory. As we can stimulate the cells with killed (inactivated) agents. Therefore this method opens a new field to stimulate the lymphocytes against the new targets e.g. recently out broken swine flu H1N1 before it breaks out in vast way as this is happening at present. This method also opens a window to create entirely new antibodies, which are not known in the literature. This technology offers the possibility to create IgM antibodies too along with IgG production.
2. In vitro immunisation of human B-lymphocytes with different antigens (secondary immunisation): In this case one can stimulate the B-lymphocytes from the blood of already exposed persons. Such application can help to create a number of applications like generating the patient specific therapies along with creating a source of long term production of human monoclonal antibodies.
3. Once one has human monoclonal antibody. This can be used as therapeutic agents or diagnostic agents. Similarly they can be converted in the magic bullets (conjugating them with toxin or drugs) to target the specific cells or tissues. They can be converted into bi-functional antibodies.
4. Our aim is create human monoclonal antibodies, which does not mount the rejection response in human being as this can be case with humanised antibodies or recombinant monoclonal antibodies.